Full history for every metric is available with a Kvantra account
ViewRay, Inc. (VRAY)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 34 | 81 | 88 | 57 | 70 | 102 | 106 |
| Operating profit | $m | -107 | -107 | |||||
| Net profit | $m | -72 | -76 | -123 | -105 | -106 | -108 | -114 |
| EPS reported | $ | -0.60 | -0.63 | |||||
| Operating cashflow per share | $ | -0.51 | -0.51 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -0.53 | -0.53 | |||||
| Free cash flow | $m | -96 | -117 | |||||
| Net debt | $m | -50 | -4 | |||||
| Book value equity | $m | 82 | 55 | |||||
| Book value per share | $ | 0.46 | 0.30 | |||||
| Number of shares | m | 180.7 | 182.31 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 9.84 | 0.08 | |||||
| P/S LTM | x | 7.92 | 0.04 | |||||
| P/FCF LTM | x | -8.47 | -0.04 | |||||
| EV/EBITDA LTM | x | -7.81 | -0.01 | |||||
| EV/Sales LTM | x | 7.44 | 0.01 | |||||
| Earnings Yield LTM | % | -13.28% | -2380.4% | |||||
| FCF Yield | % | -11.81% | -2562.2% | |||||
| Quality | ||||||||
| ROE | % | -130.75% | -85.33% | |||||
| ROIC | % | -60.29% | -60.29% | |||||
| Operating margin | % | -104.81% | -104.81% | |||||
| Gross margin | % | 9.83% | 9.83% | |||||
| FCF/Sales | % | -93.54% | -93.54% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +45.76% | +44.09% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.11 | -1.37 | |||||
| Net Debt/EBITDA | x | 0.51 | 0.51 | |||||
| EBIT/Net interest | x | -21.18 | -21.18 | |||||
| Net debt/market cap | % | -6.12% | -77.49% | |||||
| Net debt/Equity | x | -0.60 | -0.06 | |||||
| Gross debt/equity | x | 1.05 | 1.54 | |||||
Company overview
ViewRay, Inc. specializes in the development, production, and global distribution of advanced radiation therapy systems that leverage magnetic resonance imaging (MRI). These integrated systems are utilized to both image and deliver treatment for cancer patients in various countries, including the United States, France, Taiwan, and the United Kingdom. The company's key product, MRIdian, is an MRI-guided radiation therapy solution engineered to address critical concerns during treatment, such as beam distortion and potential skin toxicity. ViewRay's client base spans a diverse range of medical facilities, including university research and teaching hospitals, local community hospitals, private medical practices, government institutions, and independent cancer treatment centers. MRIdian systems are sold to these clients via ViewRay's direct sales force and through its established distribution channels. The company was founded in 2004 and operates out of its main office in Oakwood, Ohio.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ViewRay, Inc. (VRAY)
ViewRay, Inc. specializes in the development, production, and global distribution of advanced radiation therapy systems that leverage magnetic resonance imaging (MRI). These integrated systems are utilized to both image and deliver treatment for cancer patients in various countries, including the United States, France, Taiwan, and the United Kingdom. The company's key product, MRIdian, is an MRI-guided radiation therapy solution engineered to address critical concerns during treatment, such as beam distortion and potential skin toxicity. ViewRay's client base spans a diverse range of medical facilities, including university research and teaching hospitals, local community hospitals, private medical practices, government institutions, and independent cancer treatment centers. MRIdian systems are sold to these clients via ViewRay's direct sales force and through its established distribution channels. The company was founded in 2004 and operates out of its main office in Oakwood, Ohio.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free